부산대학교 도서관

Purpose: To clarify the utility of the area of residual tumor for patients with esophageal squamous cell cancer treated with neoadjuvant chemotherapy. Methods: We enrolled 186 patients with esophageal squamous cell cancer who underwent surgical resection following neoadjuvant chemotherapy at our hospital. Using digital images, we measured the area of residual tumor at the maximum plane of the specimen and divided the patient into three groups as follows: 0 (area = 0 mm2), low (area = 0–40 mm2), and high (area ≥ 40 mm2). The clinicopathological factors and prognosis were compared among these groups. Results: The median area of the residual tumor was 15.0 mm2 (range 0–1,448.8 mm2). Compared with the 0 and low group, the high group was significantly associated with poorer recurrence-free survival (all P <.001) and overall survival (P <.001 [vs. 0] and P =.017 [vs low]). The area of residual tumor, ypN, tumor regression grade, and lymphovascular invasion were independent predictors of recurrence-free survival. By dividing the patients using a combination of the area of residual tumor and lymphovascular invasion, the high and/or lymphovascular invasion (+) group displayed significantly poor recurrence-free survival than the 0 group and low/lymphovascular invasion (−) group. However, there was no significant difference in the recurrence-free survival between the 0 group and low/lymphovascular invasion (−) group. Conclusion: The area of residual tumor is a promising histopathological prognostic factor for patients with esophageal squamous cell cancer treated with neoadjuvant chemotherapy. Moreover, it is a possible candidate histopathological factor for postoperative chemotherapy selection. [ABSTRACT FROM AUTHOR]